VII

Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab

Retrieved on: 
Wednesday, July 13, 2022
Tissue factor, The New England Journal of Medicine, Sodium, Thrombosis, IV, International Society, Multimedia, Factor XI, VII, Therapy, Collagen, Congress, Anthos, Factor, CVM, Patient, Endothelium, Fast track (FDA), Aspirin, Low-density lipoprotein receptor-related protein 8, Abciximab, Private Securities Litigation Reform Act, Platelet, Blood, Haemophilia C, Glycoprotein Ib, Lists of diseases, SC, Bleeding, Research, Poster, Ticagrelor, Cancer, FXI, Pharmaceutical industry

CAMBRIDGE, Mass., July 13, 2022 /PRNewswire/ -- Anthos Therapeutics, a clinical-stage biotechnology company developing innovative therapies for cardiovascular and metabolic diseases, announced that four new research updates were presented on abelacimab during the Venous Thromboembolism poster session at the ongoing International Society on Thrombosis and Haemostasis 2022 Congress in London, UK.

Key Points: 
  • "Coagulation is a complex multilayered process and the potential benefits of inhibiting Factor XI are becoming increasingly clear.
  • It demonstrated that abelacimab did not affect the level of antiplatelet inhibition achieved either by aspirin or ticagrelor confirming that abelacimab will not interfere with the benefits of these antiplatelet agents.
  • Abelacimab is a novel, highly selective, fully human monoclonal antibody designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition.
  • Abelacimab targets the active domain of Factor XI, demonstrating dual inhibitory activity against both Factor XI and its activated form, Factor XIa.

Silverton Partners Raises Largest Fund to Date at $248M to Support Austin’s Rapidly Expanding Tech Scene

Retrieved on: 
Wednesday, July 6, 2022
Start-Up, Other Professional Services, Professional Services, Finance, VII, Silicon, Foundation, EfTEN Real Estate Fund III, Growth, History, Initial public offering, Partner, CFO, LP record, Silverton Partners, Silicon Labs, Storables

Silverton Partners , Texas most active and longest standing venture capital investor, today announced the close of Fund VII at $248M in total assets.

Key Points: 
  • Silverton Partners , Texas most active and longest standing venture capital investor, today announced the close of Fund VII at $248M in total assets.
  • It is anticipated that more than two-thirds of Fund VIIs capital will be deployed to support the rapidly growing needs of Texas-based early-stage startups.
  • Were excited to put Fund VIIs capital to work in supporting the growth of companies in Texas and beyond, said Morgan Flager, Managing Partner at Silverton Partners.
  • In total, the funds capital, raised from top university endowments and foundations, amounts to $177M in Silverton Partners VII and $71M in Silverton Opportunities II.

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

Retrieved on: 
Wednesday, June 22, 2022
Fibrosis, Skin, Concha bullosa, Review, FDA, Tears, Safety, Private Securities Litigation Reform Act, KRYS, Tissue, Priority, Squamous cell carcinoma, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Finger, Blister, Wound healing, COL7A1, Company, Securities and Exchange Commission (Philippines), Suma, Research and development, VII, Trauma, DEB, LinkedIn, BLA, Marketing, GLOBE, Lung, NASDAQ, COL7, Twitter, Food, The, EMA, Patient, Biologics license application, U.S. Securities and Exchange Commission, Dermis, Epidermis, Risk, Pharmaceutical industry, Medical device, Nature Medicine

The GEM-3 trial was a randomized, double-blind, intra-patient placebo-controlled multi-center trial designed to evaluate the efficacy and safety of B-VECfor the treatment of DEB.

Key Points: 
  • The GEM-3 trial was a randomized, double-blind, intra-patient placebo-controlled multi-center trial designed to evaluate the efficacy and safety of B-VECfor the treatment of DEB.
  • In the trial, matched wounds receiving topical B-VEC or placebo were evaluated in 31 DEB patients over 26 weeks.
  • The pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-months and its secondary endpoint of complete wound healing at three-months.
  • In the trial, matched wounds receiving topical B-VEC or placebo were evaluated in nine recessive dystrophic epidermolysis bullosa patients over 12 weeks.

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

Retrieved on: 
Wednesday, June 22, 2022
Fibrosis, Skin, Concha bullosa, Review, FDA, Tears, Safety, Private Securities Litigation Reform Act, KRYS, Tissue, Priority, Squamous cell carcinoma, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Finger, Blister, Wound healing, COL7A1, Company, Securities and Exchange Commission (Philippines), Suma, Research and development, VII, Trauma, DEB, LinkedIn, BLA, Marketing, GLOBE, Lung, NASDAQ, COL7, Twitter, Food, The, EMA, Patient, Biologics license application, U.S. Securities and Exchange Commission, Dermis, Epidermis, Risk, Pharmaceutical industry, Medical device, Nature Medicine

The GEM-3 trial was a randomized, double-blind, intra-patient placebo-controlled multi-center trial designed to evaluate the efficacy and safety of B-VECfor the treatment of DEB.

Key Points: 
  • The GEM-3 trial was a randomized, double-blind, intra-patient placebo-controlled multi-center trial designed to evaluate the efficacy and safety of B-VECfor the treatment of DEB.
  • In the trial, matched wounds receiving topical B-VEC or placebo were evaluated in 31 DEB patients over 26 weeks.
  • The pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-months and its secondary endpoint of complete wound healing at three-months.
  • In the trial, matched wounds receiving topical B-VEC or placebo were evaluated in nine recessive dystrophic epidermolysis bullosa patients over 12 weeks.

CHEQ named as Official In-Stadium Mobile Ordering and Delivery Partner of the Miami Dolphins, Hard Rock Stadium

Retrieved on: 
Tuesday, June 21, 2022
Season, Orange Bowl, Super Bowl, CHEQ, MIAMI, Baptist Health, VII, Hard Rock Stadium, Growth, VIII, Miami Dolphins, University, Table, NFL, Board, Dolphin, Multimedia, Friends, Entertainment, Online shopping

MIAMI GARDENS, Fla., June 21, 2022 /PRNewswire/ -- CHEQ Inc., the world's first social payments platform continues their growth in professional sports as they are named the official in-stadium mobile ordering and delivery partner of the Miami Dolphins and Hard Rock Stadium.

Key Points: 
  • MIAMI GARDENS, Fla., June 21, 2022 /PRNewswire/ -- CHEQ Inc., the world's first social payments platform continues their growth in professional sports as they are named the official in-stadium mobile ordering and delivery partner of the Miami Dolphins and Hard Rock Stadium.
  • "We are excited to partner with CHEQtoenhanceourfanexperiencethrough theirproventrackrecordofinnovationand technology in large scale sports venues," said Jeremy Walls, Chief Revenue Officer of the Miami Dolphins and Hard Rock Stadium.
  • CHEQ Chief Revenue Officer Jake Stone added, "The Miami Dolphins are one of the NFL's most storied and beloved teams and we are delighted to partner with them to make mobile ordering easy and ubiquitous throughout the stadium.
  • The Dolphins play home games at Hard Rock Stadium and train at the Baptist Health Training Complex in Miami Gardens.

FINAL FANTASY VII 25th ANNIVERSARY CELEBRATION BROADCAST Unveils First Look At ‘FINAL FANTASY VII REBIRTH’, ‘CRISIS CORE -FINAL FANTASY VII- REUNION’ and More

Retrieved on: 
Friday, June 17, 2022
Retail, Consumer Electronics, Technology, General Entertainment, Other Consumer, Other Entertainment, Women, Online Retail, Teens, Other Retail, Men, Electronic Games, Software, Entertainment, Consumer, Cloud, PC, SOLDIER, RPG, Stories in an Almost Classical Mode, Map, PS5, VII, Zack Fair, Intention, Final Fantasy VII Remake, Machinist, Â, PlayStation 5, Friends, Software release life cycle, Entertainment, Bookbinding, Sport, Online gambling

FINAL FANTASY VII remake series Creative Director, Tetsuya Nomura said, As revealed on the broadcast, there are currently four FINAL FANTASY VII projects being developed in parallel.

Key Points: 
  • FINAL FANTASY VII remake series Creative Director, Tetsuya Nomura said, As revealed on the broadcast, there are currently four FINAL FANTASY VII projects being developed in parallel.
  • In fact, new players might even enjoy starting their FINAL FANTASY VII journey with FINAL FANTASY VII REBIRTH.
  • Yoshinori Kitase, FINAL FANTASY VII remake series Producer and FINAL FANTASY VII Director said, We have officially announced that the second title FINAL FANTASY VII REBIRTH will be released next winter, approximately three years after the original FINAL FANTASY VII REMAKE released in April 2020.
  • The broadcast also marked the announcement of CRISIS CORE -FINAL FANTASY VII- REUNION, a remaster of PlayStationPortable exclusive, CRISIS CORE -FINAL FANTASY VII-.

Vision Impact Institute Joins Partners to Bring Good Vision to Vulnerable Populations in Panama

Retrieved on: 
Tuesday, May 24, 2022
Program, Population, Optometry, VII, Vision, Severe cognitive impairment, Non-governmental organization, Approximation error, School, DRS, Partnership, Awareness, Student, Faculty, Interamerican University of Puerto Rico, UC Berkeley School of Optometry, Life, Management

DALLAS, May 24, 2022 /PRNewswire/ -- The Vision Impact Institute (VII) is pleased to join a partnership that brings eye care services to vulnerable populations in Panama. The partnership includes Lions Club Penonome, Panama, Universidad Especializada de las Americas (UDELAS) Panama, The School of Optometry at Inter American University of Puerto Rico, Vision for Life - Essilor, Optometry Giving Sight and VOSH International.  Together these groups will conduct comprehensive eye exams, provide glasses, diagnose vision problems, gather data, and create awareness of vision health for approximately 1,500 people in Panama City's Guna Nega community.

Key Points: 
  • DALLAS, May 24, 2022 /PRNewswire/ -- The Vision Impact Institute (VII) is pleased to join a partnership that brings eye care services to vulnerable populations in Panama.
  • This creates a social and economic impact on all populations, including those that are vulnerable," says Judith Williams , Program Manager, The Americas, VII.
  • The Vision Impact Institute's mission is to raise awareness ofthe importance of vision correction and protection to make good vision a global priority.
  • The Vision Impact Institute is a registered 501(c)(3) non-profit organization, which receives support from the Vision for Life Fund from Essilor, the world leader in ophthalmic optics.

Vision Impact Institute Joins Partners to Bring Good Vision to Vulnerable Populations in Panama

Retrieved on: 
Tuesday, May 24, 2022
Program, Population, Optometry, VII, Vision, Severe cognitive impairment, Non-governmental organization, Approximation error, School, DRS, Partnership, Awareness, Student, Faculty, Interamerican University of Puerto Rico, UC Berkeley School of Optometry, Life, Management

DALLAS, May 24, 2022 /PRNewswire/ -- The Vision Impact Institute (VII) is pleased to join a partnership that brings eye care services to vulnerable populations in Panama. The partnership includes Lions Club Penonome, Panama, Universidad Especializada de las Americas (UDELAS) Panama, The School of Optometry at Inter American University of Puerto Rico, Vision for Life - Essilor, Optometry Giving Sight and VOSH International.  Together these groups will conduct comprehensive eye exams, provide glasses, diagnose vision problems, gather data, and create awareness of vision health for approximately 1,500 people in Panama City's Guna Nega community.

Key Points: 
  • DALLAS, May 24, 2022 /PRNewswire/ -- The Vision Impact Institute (VII) is pleased to join a partnership that brings eye care services to vulnerable populations in Panama.
  • This creates a social and economic impact on all populations, including those that are vulnerable," says Judith Williams , Program Manager, The Americas, VII.
  • The Vision Impact Institute's mission is to raise awareness ofthe importance of vision correction and protection to make good vision a global priority.
  • The Vision Impact Institute is a registered 501(c)(3) non-profit organization, which receives support from the Vision for Life Fund from Essilor, the world leader in ophthalmic optics.

BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Retrieved on: 
Friday, May 20, 2022
Disease, Research, Food, Pain management, Trauma, SID, Lists of diseases, Drug Quality and Security Act, Twitter, SEC, PHASE 2, Mouth, Annual report, Epidermis, Pain, VII, Bart syndrome, Clinical trial, Securities Act of 1933, Intention, Securities Exchange Act of 1934, Genetic disorder, Acid erosion, GLOBE, Concha bullosa, Epidermolysis bullosa, Survival, Tongue, DEB, Science, Patient, RDEB, Lewis Milestone, DEJ, Eye, C7, FDA, European Medicines Agency, PALO, Skin, Society, LinkedIn, Squamous cell carcinoma, Genetic distance, Radioactive decay, Cancer, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nasdaq, Environment, Poster, Esophagus, Tearing, Safety, Wound healing, Malnutrition, Instrument, Scar, Pharmaceutical industry, Dentistry, Medical imaging

PALO ALTO, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair, which is focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB), announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB). The data are being shared in a poster at the Society for Investigative Dermatology (SID) Annual Meeting 2022 between May 18 – 21, 2022 in Portland, Oregon.

Key Points: 
  • Our data shows that treatment with PTR-01 led to rapid, consistent, and durable wound healing, said Sanuj K. Ravindran, M.D., executive chairman of Phoenix Tissue Repair.
  • Phoenix Tissue Repair is an affiliate company of BridgeBio and focused on advancing a novel systemic treatment for recessive dystrophic epidermolysis bullosa (RDEB).
  • PTR-01 is an investigational protein replacement therapy which uses a recombinant collagen type VII (rC7) for the treatment of RDEB.
  • Moreover, BridgeBio and Phoenix Tissue Repair operate in very competitive and rapidly changing environments in which new risks emerge from time to time.

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

Retrieved on: 
Friday, May 20, 2022
The, Epidermis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Concha bullosa, Risk, Company, Disease, VII, Food, Finger, DEB, Skin, Patient, Poster, COL7, NASDAQ, Trauma, Dermis, Degenerative disease, FDA, Fibrosis, Booth, Blister, COL7A1, EMA, KRYS, Tears, Priority, Lung, LinkedIn, Society, Twitter, Squamous cell carcinoma, Tissue, GLOBE, Medical device, Vaccine, Pharmaceutical industry

To register for the conference, please visit SID 2022 Annual Meeting | Society for Investigative Dermatology .

Key Points: 
  • To register for the conference, please visit SID 2022 Annual Meeting | Society for Investigative Dermatology .
  • The Company will be present at Booth 218 to educate about DEB and the mechanism of the disease.
  • Following the presentation, materials will be available to view online on the Investor section of the Companys website .
  • Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) have each granted B-VEC an orphan drug designation for the treatment of DEB.